Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2001

01-12-2001 | Review

Update on HER-2 as a target for cancer therapy: Alternative strategies for targeting the epidermal growth factor system in cancer

Author: William J Gullick

Published in: Breast Cancer Research | Issue 6/2001

Login to get access

Abstract

The epidermal growth factor (EGF) family of ligands and receptors interact to influence cell division, differentiation and motility. Much evidence supports their importance in causing and sustaining cell transformation in model systems and in human cancer. The exact mechanism by which this is achieved varies in different tumour types and from case to case. The EGF system is a target for new types of targeted chemotherapy. The choice of strategy will depend on the mechanism involved, however, and several approaches are under development or evaluation in clinical trials. Each will have a different spectrum of side effects and the potential for development of drug resistance.
Literature
1.
Lu H-S, Chai J-J, Huang B-R, He C-H, Bi R-C: Crystal structure of the human epidermal growth factor and its dimerisation. J Biol Chem. 2001, 276: 34913-34917. 10.1074/jbc.M102874200.CrossRefPubMed
2.
Cooke RM, Wilkinson AJ, Baron M, Pastore A, Tappin MJ, Campbell ID, Gregory H, Sheard B: The solution structure of human epidermal growth factor. Nature. 1987, 327: 339-341. 10.1038/327339a0.CrossRefPubMed
3.
Gullick WJ: The type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer. 2001, 8: 75-82.CrossRefPubMed
4.
Cohen S: EGF and its receptor: historical perspective. J Mammary Gland Biol Neoplasia. 1997, 2: 93-96. 10.1023/A:1026391412129.CrossRefPubMed
5.
Deuel TF, Huang JS, Huang SS, Stroobant P, Waterfield MD: Expression of a platelet-derived growth factor-like protein in simian sarcoma virus transformed cells. Science. 1983, 21: 1348-1350.CrossRef
6.
Robbins KC, Antoniades HN, Devare SG, Hunkapiller MW, Aaron-son SA: Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor. Nature. 1983, 305: 605-608.CrossRefPubMed
7.
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984, 307: 521-527.CrossRefPubMed
8.
9.
Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ: Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res. 1999, 5: 2877-2883.PubMed
10.
McKay IA, Malone P, Marshall CJ, Hall A: Malignant transformation of murine fibroblasts by a human c-Ha-ras-1 oncogene does not require a functional epidermal growth factor receptor. Mol Cell Biol. 1986, 6: 3382-3387.CrossRefPubMedPubMedCentral
11.
Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001, 8: 11-31.CrossRefPubMed
12.
Lohmeyer M, Gullick WJ: Mutational activation of receptor tyrosine kinases. In: Hormones and Growth Factors in Development and Neoplasia. Edited by Dickson RB, Salomon DS. New York: John Wiley and Sons, Inc.;. 1998, 289-309.
13.
Kuan CT, Wikstrand CJ, Bigner DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001, 8: 83-96.CrossRefPubMed
14.
Hills D, Rowlinson-Busza G, Gullick WJ: Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer. 1995, 63: 537-543.CrossRefPubMed
15.
Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19: 6550-6565. 10.1038/sj.onc.1204082.CrossRefPubMed
16.
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61: 4744-4749.PubMed
17.
Pastan II, Kreitman RJ: Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev. 1998, 31: 53-88. 10.1016/S0169-409X(97)00094-X.CrossRefPubMed
18.
Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS: Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001, 21: 4265-4275. 10.1128/MCB.21.13.4265-4275.2001.CrossRefPubMedPubMedCentral
Metadata
Title
Update on HER-2 as a target for cancer therapy: Alternative strategies for targeting the epidermal growth factor system in cancer
Author
William J Gullick
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr328

Other articles of this Issue 6/2001

Breast Cancer Research 6/2001 Go to the issue

Review

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition

Review

Tumour-stroma interactions: Phenotypic and genetic alterations in mammary stroma: implications for tumour progression

Commentary

Wnt signaling in breast cancer: have we come full circle?

Commentary

PTEN deficiency: a role in mammary carcinogenesis

Meeting report

Reasons for Hope: Canadian Breast Cancer Research Conference, Le Concorde Hotel, Quebec City, Quebec, Canada, 3–5 May 2001

Commentary

Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits